The drug Kaftrio for the treatment of cystic fibrosis will be fully reimbursed from February 1, 2025 for children aged 2 to 5, resigned Federal Minister of Health Frank Vandenbroucke said on Thursday. This reimbursement had already been extended in February 2023 to children aged 6 to 11.
This reimbursement specifically concerns the medicine Kaftrio. This has been reimbursed since September 1, 2022 for people with cystic fibrosis over the age of 12 with at least one F508del mutation. Reimbursement was extended less than a year later to minors aged 6 to 11. Children aged 2 to 5 will now also be affected by this measure, which represents around 70 young people.
Cystic fibrosis is a serious disease that has a major impact on the burden of morbidity and the quality of life of patients. Several clinical studies show that the drug Kaftrio optimizes lung function, reduces the use of antibiotics and improves the quality of life of patients.
The office of the Minister of Health specifies that clinical trials are underway for the use of Kaftrio on children from the age of one, but these should last several years. Furthermore, the firm confirms that it is examining the possibility of reimbursement of the drug for people suffering from cystic fibrosis without at least one F508del mutation. A decision should be made before summer, he promises.
Finally, reimbursement of another drug for patients with cystic fibrosis, Orkambi, will not be extended for children aged one to two years, due to lack of an agreement with the company that produces this treatment. This measure would have concerned 11 children, specifies Mr. Vandenbroucke's office.
Access to all features is reserved for healthcare professionals.
If you are a healthcare professional you must log in or register for free on our site to access all of our content.
If you are a journalist or if you wish to inform us, write to us at [email protected].
Health
